Dexrazoxane from Cumberland Pharmaceuticals approved for U.S. oncology patients

Totect is approved by the U.S. Food and Drug Administration as an oncology intervention. | File photo

Cumberland Pharmaceuticals, specializing in therapies for underserved populations, has begun shipping its Totect brand of dexrazoxane, for alleviating certain side effects of chemotherapy during cancer treatment, to U.S. wholesalers.

As the firm’s second oncology remedy, Totect supports Cumberland Pharmaceuticals’ existing specialty product pipeline. The treatment is licensed to Cumberland under a contract with Clinigen, allowing Cumberland oversight of marketing, promotion and distribution nationwide.

"We are delighted to make Totect (dexrazoxane) available for oncology patients throughout the U.S.," Cumberland Pharmaceuticals CEO A.J. Kazimi said. "We look forward to continuing to expand our activities into oncology while working to deliver products that improve the quality of care for patients."

The treatment falls into a class of medications called anthracycline extravasation agents. Anthracyclines are commonly used in chemotherapy; occasionally, extravasation (leakage of anthracycline into surrounding tissues) occurs.

Totect is approved by the U.S. Food and Drug Administration as an oncology intervention specifically to minimize complications in case of extravasation. If untreated, side effects can quickly become serious and may include tissue necrosis, skin ulceration, and possibly damage to nerves, tendons, muscle and/or joints.

Cumberland focuses its portfolio on products serving acute care in hospitals and gastroenterology. It also markets medications addressing acetaminophen poisoning; pain and fever; and more.

Want to get notified whenever we write about
Cumberland Pharmaceuticals Inc.
?

Next time we write about
Cumberland Pharmaceuticals Inc.,
we'll email you a link to the story. You may edit your settings or unsubscribe at any time.